ESC 365 - Why do we need additional long-term antithrombotic therapy with Coronary Artery Disease and Peripheral Artery Disease?

ESC Premium Access

Why do we need additional long-term antithrombotic therapy with Coronary Artery Disease and Peripheral Artery Disease?

Session: Setting the COMPASS into new directions

Topic: Treatment

Speaker: Professor K. Fox (Edinburgh, GB)

Sponsored by Bayer AG

Event: ESC Congress 2018

Congress Presentation

About the speaker

Professor Keith Fox

University of Edinburgh, Edinburgh (United Kingdom of Great Britain & Northern Ireland)

36 presentations

0 follower

5 more presentations in this session

A paradigm shift becoming reality.

Speaker: Doctor S. Yusuf (Hamilton, CA)

Industry Digest

Improved outcomes for patients with chronic Coronary Artery Disease and Peripheral Artery Disease

Speaker: Doctor J. Eikelboom (Hamilton, CA)

Industry Digest

How to improve outcomes in patients with coronary artery disease and peripheral artery disease.

Speaker: Professor S. Anand (Hamilton, CA)

Question & Answer and interactive session.

Speaker: Doctor S. Yusuf (Hamilton, CA)

Industry Digest

Closing remarks - Setting the COMPASS into new directions

Speaker: Professor K. Fox (Edinburgh, GB)

Industry Digest

Access the full session

Setting the COMPASS into new directions

Speakers: Professor K. Fox, Doctor S. Yusuf, Doctor J. Eikelboom, Professor S. Anand, Doctor S. Yusuf...

About the event

ESC Congress 2018

7 November - 29 August 2018

Sessions Presentations

Congress

Related content

Open Access

Integrating EPA based therapy in the management of residual risk.

29 August 2021

Open Access

How the new guidance will impact the treatment of elderly atrial fibrillation patients in clinical practice.

28 August 2021

Open Access

What is new in the 2021 EHRA Practical Guide on the use of NOACs in patients with atrial fibrillation.

28 August 2021

ESC 365 is supported by